CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 46 enrolled / 46 target
Drug / intervention
Cyclophosphamide +10 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03220022
NCT03220022Phase 1ActiveUpdate Overdue (0.5/mo)Completion was 20mo ago

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

National Cancer Institute (NCI)·interventional·Posted Jul 18, 2017·Updated Jun 26, 2026

In Brief

A Phase 1 clinical trial evaluating Cyclophosphamide, Doxorubicin Hydrochloride, and 9 other interventions for AIDS-Related Lymphoma and 3 related conditions. Active but no longer recruiting, targeting 46 participants across 19 sites.

Signals

Enrollment appears stalled

Detailed Summary

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1Active
201820192020202120222023202420252026
First PostedJul 18, 2017
Enrollment StartMar 16, 2018
Primary CompletionOct 10, 2024
Study CompletionJul 16, 2026
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 9.0 years ago

Arms & Interventions

Treatment (R-da-EPOCH)experimental

Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.

Drug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideBiological: FilgrastimDrug: IbrutinibOther: Laboratory Biomarker AnalysisBiological: PegfilgrastimOther: Pharmacological StudyDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate

Interventions

Cyclophosphamidedrug

Given IV

Doxorubicin Hydrochloridedrug

Given IV

Etoposidedrug

Given IV

Filgrastimbiological

Given SC

Ibrutinibdrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Pegfilgrastimbiological

Given SC

Pharmacological Studyother

Correlative studies

Prednisonedrug

Given PO

Rituximabbiological

Given IV

Vincristine Sulfatedrug

Given IV